Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection

Maria Francesca Donato, C. Degott, E. Arosio, M. Martinot, V. Monti, A. Morabito, P. Marcellin, M. Colombo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Interferon (IFN) therapy has been shown to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C, including virological nonresponders (NR). Whether IFN suppresses liver cell proliferation, i.e. the relevant risk factor for HCC, is unknown. The aim of the study was to evaluate the effect of IFN therapy on liver cell proliferation in chronic hepatitis C. The proliferating cell nuclear antigen-labelling index (PCNA-LI) was assessed prior to and at the end of therapy in the liver of 29 patients with chronic hepatitis C who received 3 MU IFN-α2b thrice weekly for 24-48 weeks. Overall, the median value of PCNA-LI was significantly reduced from 2.6% to 1.1% at the end of therapy (P <0.0001). At baseline, PCNA-LI median values were similar in the 15 virological responders compared with the 14 NRs (2.3% vs 3.4%, P = 0.121) and at the end of therapy, median changes of PCNA-LI (-1.4% vs -1.1%, P = 0.089) were also similar although there was a higher decline of the proliferation index in responders with respect to NRs at the end of therapy (0.7% vs 1.6%, P = 0.004). In the two groups, the rate of fibrosis score reduction was also similar (7% vs 20%, P = 0.326). In contrast, the histological activity index was more often reduced in responders than in NRs both at the >2 and >4 points reduction level (80% vs 36%, P = 0.02 and 53% vs 14%, P = 0.03, respectively). The study showed a significant suppression of liver cell proliferation in IFN-treated patients with chronic hepatitis C. Although the strongest IFN effect was observed in virological responders, a reduction of proliferative activity was also seen in virological NRs.

Original languageEnglish
Pages (from-to)499-506
Number of pages8
JournalJournal of Viral Hepatitis
Volume12
Issue number5
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Interferons
Cell Proliferation
Liver
Proliferating Cell Nuclear Antigen
Hepatocellular Carcinoma
Therapeutics

Keywords

  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Histological activity index
  • Interferon
  • Liver cell proliferation

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection. / Donato, Maria Francesca; Degott, C.; Arosio, E.; Martinot, M.; Monti, V.; Morabito, A.; Marcellin, P.; Colombo, M.

In: Journal of Viral Hepatitis, Vol. 12, No. 5, 09.2005, p. 499-506.

Research output: Contribution to journalArticle

Donato, Maria Francesca ; Degott, C. ; Arosio, E. ; Martinot, M. ; Monti, V. ; Morabito, A. ; Marcellin, P. ; Colombo, M. / Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection. In: Journal of Viral Hepatitis. 2005 ; Vol. 12, No. 5. pp. 499-506.
@article{e9a3d87dc35e444da651264c4714373d,
title = "Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection",
abstract = "Interferon (IFN) therapy has been shown to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C, including virological nonresponders (NR). Whether IFN suppresses liver cell proliferation, i.e. the relevant risk factor for HCC, is unknown. The aim of the study was to evaluate the effect of IFN therapy on liver cell proliferation in chronic hepatitis C. The proliferating cell nuclear antigen-labelling index (PCNA-LI) was assessed prior to and at the end of therapy in the liver of 29 patients with chronic hepatitis C who received 3 MU IFN-α2b thrice weekly for 24-48 weeks. Overall, the median value of PCNA-LI was significantly reduced from 2.6{\%} to 1.1{\%} at the end of therapy (P <0.0001). At baseline, PCNA-LI median values were similar in the 15 virological responders compared with the 14 NRs (2.3{\%} vs 3.4{\%}, P = 0.121) and at the end of therapy, median changes of PCNA-LI (-1.4{\%} vs -1.1{\%}, P = 0.089) were also similar although there was a higher decline of the proliferation index in responders with respect to NRs at the end of therapy (0.7{\%} vs 1.6{\%}, P = 0.004). In the two groups, the rate of fibrosis score reduction was also similar (7{\%} vs 20{\%}, P = 0.326). In contrast, the histological activity index was more often reduced in responders than in NRs both at the >2 and >4 points reduction level (80{\%} vs 36{\%}, P = 0.02 and 53{\%} vs 14{\%}, P = 0.03, respectively). The study showed a significant suppression of liver cell proliferation in IFN-treated patients with chronic hepatitis C. Although the strongest IFN effect was observed in virological responders, a reduction of proliferative activity was also seen in virological NRs.",
keywords = "Hepatitis C virus, Hepatocellular carcinoma, Histological activity index, Interferon, Liver cell proliferation",
author = "Donato, {Maria Francesca} and C. Degott and E. Arosio and M. Martinot and V. Monti and A. Morabito and P. Marcellin and M. Colombo",
year = "2005",
month = "9",
doi = "10.1111/j.1365-2893.2005.00625.x",
language = "English",
volume = "12",
pages = "499--506",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection

AU - Donato, Maria Francesca

AU - Degott, C.

AU - Arosio, E.

AU - Martinot, M.

AU - Monti, V.

AU - Morabito, A.

AU - Marcellin, P.

AU - Colombo, M.

PY - 2005/9

Y1 - 2005/9

N2 - Interferon (IFN) therapy has been shown to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C, including virological nonresponders (NR). Whether IFN suppresses liver cell proliferation, i.e. the relevant risk factor for HCC, is unknown. The aim of the study was to evaluate the effect of IFN therapy on liver cell proliferation in chronic hepatitis C. The proliferating cell nuclear antigen-labelling index (PCNA-LI) was assessed prior to and at the end of therapy in the liver of 29 patients with chronic hepatitis C who received 3 MU IFN-α2b thrice weekly for 24-48 weeks. Overall, the median value of PCNA-LI was significantly reduced from 2.6% to 1.1% at the end of therapy (P <0.0001). At baseline, PCNA-LI median values were similar in the 15 virological responders compared with the 14 NRs (2.3% vs 3.4%, P = 0.121) and at the end of therapy, median changes of PCNA-LI (-1.4% vs -1.1%, P = 0.089) were also similar although there was a higher decline of the proliferation index in responders with respect to NRs at the end of therapy (0.7% vs 1.6%, P = 0.004). In the two groups, the rate of fibrosis score reduction was also similar (7% vs 20%, P = 0.326). In contrast, the histological activity index was more often reduced in responders than in NRs both at the >2 and >4 points reduction level (80% vs 36%, P = 0.02 and 53% vs 14%, P = 0.03, respectively). The study showed a significant suppression of liver cell proliferation in IFN-treated patients with chronic hepatitis C. Although the strongest IFN effect was observed in virological responders, a reduction of proliferative activity was also seen in virological NRs.

AB - Interferon (IFN) therapy has been shown to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C, including virological nonresponders (NR). Whether IFN suppresses liver cell proliferation, i.e. the relevant risk factor for HCC, is unknown. The aim of the study was to evaluate the effect of IFN therapy on liver cell proliferation in chronic hepatitis C. The proliferating cell nuclear antigen-labelling index (PCNA-LI) was assessed prior to and at the end of therapy in the liver of 29 patients with chronic hepatitis C who received 3 MU IFN-α2b thrice weekly for 24-48 weeks. Overall, the median value of PCNA-LI was significantly reduced from 2.6% to 1.1% at the end of therapy (P <0.0001). At baseline, PCNA-LI median values were similar in the 15 virological responders compared with the 14 NRs (2.3% vs 3.4%, P = 0.121) and at the end of therapy, median changes of PCNA-LI (-1.4% vs -1.1%, P = 0.089) were also similar although there was a higher decline of the proliferation index in responders with respect to NRs at the end of therapy (0.7% vs 1.6%, P = 0.004). In the two groups, the rate of fibrosis score reduction was also similar (7% vs 20%, P = 0.326). In contrast, the histological activity index was more often reduced in responders than in NRs both at the >2 and >4 points reduction level (80% vs 36%, P = 0.02 and 53% vs 14%, P = 0.03, respectively). The study showed a significant suppression of liver cell proliferation in IFN-treated patients with chronic hepatitis C. Although the strongest IFN effect was observed in virological responders, a reduction of proliferative activity was also seen in virological NRs.

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Histological activity index

KW - Interferon

KW - Liver cell proliferation

UR - http://www.scopus.com/inward/record.url?scp=24044531268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044531268&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2005.00625.x

DO - 10.1111/j.1365-2893.2005.00625.x

M3 - Article

C2 - 16108765

AN - SCOPUS:24044531268

VL - 12

SP - 499

EP - 506

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 5

ER -